



**SERES**  
THERAPEUTICS™

## **Seres Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference**

January 4, 2024

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 4, 2024-- [Seres Therapeutics, Inc.](#) (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Seres management will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 10, 2024, at 12:45 p.m. ET / 9:45 am PT.

An audio webcast of the presentation will be available under the "Investors and News" section of Seres' website. A replay of the presentation will become available approximately one hour after the event and will be archived for 21 days.

### **About Seres Therapeutics**

Seres Therapeutics, Inc. (Nasdaq: MCRB) is a commercial-stage company developing novel microbiome therapeutics for serious diseases. Seres' lead program, VOWST™, obtained U.S. FDA approval in April 2023 as the first orally administered microbiome therapeutic to prevent recurrence of *C. difficile* infection (CDI) in adults following antibacterial treatment for recurrent CDI and is being commercialized in collaboration with Nestlé Health Science. Seres is evaluating SER-155 in a Phase 1b study in patients receiving allogeneic hematopoietic stem cell transplantation. For more information, please visit [www.serestherapeutics.com](http://www.serestherapeutics.com).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20240104551305/en/): <https://www.businesswire.com/news/home/20240104551305/en/>

### **Investor and Media Contact:**

Rob Windsor

[rwindsor@serestherapeutics.com](mailto:rwindsor@serestherapeutics.com)

Source: Seres Therapeutics, Inc.